YieldMax AI & Tech Portfolio Option Income ETF vs Liquidia Corporation Common Stock — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $40 (market cap $139.69M), while Liquidia Corporation Common Stock trades at $34 (market cap $3.04B). The key difference: Liquidia Corporation Common Stock is far larger — about 21.8× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 62 Days and Liquidia Corporation Common Stock for 0 Days on average.
| GPTY | LQDA | |
|---|---|---|
Market Cap | $139.69M | $3.04B |
Volume | 81,745 | 21,111,778 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $91.03 |
52-Week Low | $34.73 | $22.02 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | — | $2.94B |
Signals from Pluang's Aura AI — not financial advice
GPTY, a US stock, trades at $42.44, up 0.05% in the last 24 hours. The technical outlook is bearish based on moving averages, with key support at $42 and resistance at $43. Recent news highlights the ETF's weekly dividend distributions and a Seeking Alpha article from August 2026 rating it a Buy for high AI-driven income, citing its covered call spread strategy.
The outlook for GPTY is mixed, with a high-yield income opportunity from consistent dividends but tempered by bearish technical signals and limited fundamental data. Risks include market volatility and dependence on options strategies, while institutional interest remains a potential catalyst.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →